207 related articles for article (PubMed ID: 25559683)
1. Anti-JC virus antibodies in rituximab-treated patients with neuromyelitis optica spectrum disorder.
Kim SH; Hyun JW; Jeong IH; Joung A; Yeon JL; Dehmel T; Adams O; Kieseier BC; Kim HJ
J Neurol; 2015 Mar; 262(3):696-700. PubMed ID: 25559683
[TBL] [Abstract][Full Text] [Related]
2. Anti-JC virus antibody index changes in rituximab-treated multiple sclerosis patients.
Baber U; Bouley A; Egnor E; Sloane JA
J Neurol; 2018 Oct; 265(10):2342-2345. PubMed ID: 30109480
[TBL] [Abstract][Full Text] [Related]
3. Serum anti-John Cunningham virus antibody seroprevalence and index among Japanese patients with neuromyelitis optica spectrum disorders.
Aoyama S; Mori M; Uzawa A; Uchida T; Masuda H; Ohtani R; Kuwabara S
Mult Scler; 2020 Jan; 26(1):128-129. PubMed ID: 30362874
[No Abstract] [Full Text] [Related]
4. Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica: Influence of FCGR3A Polymorphisms on the Therapeutic Response to Rituximab.
Kim SH; Jeong IH; Hyun JW; Joung A; Jo HJ; Hwang SH; Yun S; Joo J; Kim HJ
JAMA Neurol; 2015 Sep; 72(9):989-95. PubMed ID: 26167726
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy.
Vennegoor A; van Rossum JA; Polman CH; Wattjes MP; Killestein J
Mult Scler; 2015 Oct; 21(12):1600-3. PubMed ID: 25662344
[TBL] [Abstract][Full Text] [Related]
6. Systematic review of the published data on the worldwide prevalence of John Cunningham virus in patients with multiple sclerosis and neuromyelitis optica.
Paz SPC; Branco L; Pereira MAC; Spessotto C; Fragoso YD
Epidemiol Health; 2018; 40():e2018001. PubMed ID: 29370683
[TBL] [Abstract][Full Text] [Related]
7. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort.
Trampe AK; Hemmelmann C; Stroet A; Haghikia A; Hellwig K; Wiendl H; Goelz S; Ziegler A; Gold R; Chan A
Neurology; 2012 May; 78(22):1736-42. PubMed ID: 22592369
[TBL] [Abstract][Full Text] [Related]
8. Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up.
Evangelopoulos ME; Andreadou E; Koutsis G; Koutoulidis V; Anagnostouli M; Katsika P; Evangelopoulos DS; Evdokimidis I; Kilidireas C
J Neurol Sci; 2017 Jan; 372():92-96. PubMed ID: 28017256
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial.
Nikoo Z; Badihian S; Shaygannejad V; Asgari N; Ashtari F
J Neurol; 2017 Sep; 264(9):2003-2009. PubMed ID: 28831548
[TBL] [Abstract][Full Text] [Related]
10. A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification.
Lee P; Plavina T; Castro A; Berman M; Jaiswal D; Rivas S; Schlain B; Subramanyam M
J Clin Virol; 2013 Jun; 57(2):141-6. PubMed ID: 23465394
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial.
Tahara M; Oeda T; Okada K; Kiriyama T; Ochi K; Maruyama H; Fukaura H; Nomura K; Shimizu Y; Mori M; Nakashima I; Misu T; Umemura A; Yamamoto K; Sawada H
Lancet Neurol; 2020 Apr; 19(4):298-306. PubMed ID: 32199095
[TBL] [Abstract][Full Text] [Related]
12. The effect of plasma exchange on serum anti-JC virus antibodies.
Subramanyam M; Plavina T; Khatri BO; Fox RJ; Goelz SE
Mult Scler; 2013 Jun; 19(7):912-9. PubMed ID: 23232602
[TBL] [Abstract][Full Text] [Related]
13. Anti-JC virus seroprevalence in a Finnish MS cohort.
Kolasa M; Hagman S; Verkkoniemi-Ahola A; Airas L; Koivisto K; Elovaara I
Acta Neurol Scand; 2016 May; 133(5):391-7. PubMed ID: 26347001
[TBL] [Abstract][Full Text] [Related]
14. Stability and predictive value of anti-JCV antibody index in multiple sclerosis: A 6-year longitudinal study.
Hegen H; Auer M; Bsteh G; Di Pauli F; Plavina T; Walde J; Deisenhammer F; Berger T
PLoS One; 2017; 12(3):e0174005. PubMed ID: 28319193
[TBL] [Abstract][Full Text] [Related]
15. Conversion and reversion of anti-John Cunningham virus antibody serostatus: A prospective study.
Auer M; Hegen H; Sellner J; Oppermann K; Bsteh G; Di Pauli F; Berger T; Deisenhammer F
Brain Behav; 2019 Jul; 9(7):e01332. PubMed ID: 31168964
[TBL] [Abstract][Full Text] [Related]
16. Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders.
Mealy MA; Kim SH; Schmidt F; López R; Jimenez Arango JA; Paul F; Wingerchuk DM; Greenberg BM; Kim HJ; Levy M
Mult Scler; 2018 Nov; 24(13):1737-1742. PubMed ID: 28857723
[TBL] [Abstract][Full Text] [Related]
17. Individualized B cell-targeting therapy for neuromyelitis optica spectrum disorder.
Kim SH; Hyun JW; Kim HJ
Neurochem Int; 2019 Nov; 130():104347. PubMed ID: 30513364
[TBL] [Abstract][Full Text] [Related]
18. Association between soluble L-selectin and anti-JCV antibodies in natalizumab-treated relapsing-remitting MS patients.
Basnyat P; Hagman S; Kolasa M; Koivisto K; Verkkoniemi-Ahola A; Airas L; Elovaara I
Mult Scler Relat Disord; 2015 Jul; 4(4):334-8. PubMed ID: 26195052
[TBL] [Abstract][Full Text] [Related]
19. Rituximab-induced interstitial lung disease in a patient with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder.
Ahn SH; Kim SM; Sung JJ
Mult Scler Relat Disord; 2018 Feb; 20():192-193. PubMed ID: 29414297
[TBL] [Abstract][Full Text] [Related]
20. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder.
Yang Y; Wang CJ; Wang BJ; Zeng ZL; Guo SG
J Neurol Sci; 2018 Feb; 385():192-197. PubMed ID: 29406904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]